Qureshi Muhammad Ahmad, Amir Maaz, Bakht Danyal, Ali Khawar, Asif Ahmed, Bakht Kinza, Sarmad Muhammad, Tahir Maleeha, Shahid Affaf, Rehmani Maria, Awais Muhammad Numan, Haseeb Shahan, Bokhari Syed Faqeer Hussain, Ali Muhammad Khan Buhadur
Henry Ford Jackson Hospital, Jackson, MI.
King Edward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan.
Medicine (Baltimore). 2025 Sep 5;104(36):e44232. doi: 10.1097/MD.0000000000044232.
Mitral valve surgery is a widely performed intervention for the treatment of various mitral valve pathologies. Postoperative conduction disturbances may necessitate permanent pacemaker (PPM) implantation. This study aims to identify and quantify patient-related, cardiovascular, procedural risk factors, and risk score-based predictors of PPM implantation following mitral valve surgery.
The conduct of this systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines. A systematic literature search was performed across PubMed, Cochrane Library, Google Scholar, and Embase, including studies published from inception until September 2024. Statistical analyses were conducted using RevMan 5.4 software.
The meta-analysis included 8 studies totaling 39,634 patients (PPM: 3417; no PPM: 36,217) and revealed multiple significant predictors of postoperative PPM implantation. Among demographics, advanced age (mean difference [MD] 3.54; P < .00001) and female sex (odds ratio [OR] 1.19; P < .00001) were found as independent risk factors. Comorbidities included hypertension (OR 1.71, P < .00001), diabetes (OR 1.96, P < .00001), renal disease (OR 1.96, P < .00001), preexisting atrial fibrillation (OR 1.82, P < .00001), prior stroke (OR 1.57, P < .00001), chronic lung disease (OR 1.38, P < .00001), peripheral vascular disease (OR 2.03, P = .01), and smoking history (OR 1.19, P < .0001). Cardiovascular predictors comprised mitral stenosis (OR 1.77, P <.00001), prior cardiac surgery (OR 1.48, P = .0002), New York Heart Association class III/IV (OR 1.38, P = .005), and New York Heart Association class I (OR 0.64, P = .03). Procedural factors showed longer cardiopulmonary bypass time (MD 9.89, P < .00001) and aortic cross-clamp duration (MD 11.96, P < .00001) increasing risk, along with concomitant atrial fibrillation ablation (OR 1.34, P = .002). Increased society of thoracic surgeons' mortality risk (MD 1.14%, P = .04) and EuroScore (MD 2.16, P = .0005), both effectively predicted PPM need.
This meta-analysis represents the first comprehensive evaluation of risk factors associated with PPM implantation in patients undergoing mitral valve surgery. Several significant risk factors have been identified, warranting further research to validate and expand upon these findings.
二尖瓣手术是治疗各种二尖瓣病变的一种广泛开展的干预措施。术后传导障碍可能需要植入永久起搏器(PPM)。本研究旨在识别和量化与二尖瓣手术后PPM植入相关的患者相关、心血管、手术风险因素以及基于风险评分的预测因素。
本系统评价和荟萃分析遵循系统评价和荟萃分析的首选报告项目报告指南。在PubMed、Cochrane图书馆、谷歌学术和Embase上进行了系统的文献检索,包括从开始到2024年9月发表的研究。使用RevMan 5.4软件进行统计分析。
荟萃分析纳入了8项研究,共39634例患者(PPM:3417例;未植入PPM:36217例),并揭示了术后PPM植入的多个显著预测因素。在人口统计学因素中,高龄(平均差[MD] 3.54;P <.00001)和女性(比值比[OR] 1.19;P <.00001)被发现为独立风险因素。合并症包括高血压(OR 1.71,P <.00001)、糖尿病(OR 1.96,P <.00001)、肾病(OR 1.96,P <.00001)、既往房颤(OR 1.82,P <.00001)、既往中风(OR 1.57,P <.00001)、慢性肺病(OR 1.38,P <.00001)、外周血管疾病(OR 2.03,P =.01)和吸烟史(OR 1.19,P <.0001)。心血管预测因素包括二尖瓣狭窄(OR 1.77,P <.00001)、既往心脏手术(OR 1.48,P =.0002)、纽约心脏协会III/IV级(OR 1.38,P =.005)和纽约心脏协会I级(OR 0.64,P =.03)。手术因素显示,体外循环时间延长(MD 9.89,P <.00001)和主动脉阻断时间延长(MD 11.96,P <.00001)会增加风险,同时合并房颤消融(OR 1.34,P =.002)。胸外科医师协会死亡率风险增加(MD 1.14%,P =.04)和欧洲心脏手术风险评估系统评分增加(MD 2.16,P =.0005)均有效预测了PPM的需求。
本荟萃分析是对二尖瓣手术患者PPM植入相关风险因素的首次综合评估。已确定了几个显著的风险因素,需要进一步研究以验证和扩展这些发现。